Pharmacogenetics has received considerable attention in recent medical news. Extensive research has been conducted to better understand how an individual patient may respond to and benefit from a particular drug. The clinical application of pharmacogenetics, like other medical advances, requires scientific validation and established clinical utility for widespread use among patients, prescribers, and payers. This activity reviews factors that contribute to the successful integration of pharmacogenetics in clinical practice, from the drug development process all the way to the patient.
EichelbaumMIngelman-SundbergMEvansWE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119–137.
2.
EvansWEMcLeodHL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–549.
3.
GardinerSJBeggEJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521–590.
4.
AquilanteCLZinehIBeitelsheesALLangaeeTY. Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm. 2006;63:2101–2110.
5.
WeinshilboumR. Inheritance and drug response. N Engl J Med. 2003;348:529–537.
6.
FargherEATrickerKNewmanWCurrent use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Therapeutics. 2007;32:187–195.
7.
VeenstraDLHigashiMKPhillipsKA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2:E29.
8.
MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet. 2002;359:727–732.
9.
HetheringtonSHughesARMostellerMGenetic variations in HLA-B region and hyper-sensitivity reactions to abacavir. Lancet. 2002;359:1121–1122.
10.
HughesDAVilarFJWardCCAlfirevicAParkBKPirmohamedM. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14:335–342.
11.
MallalSPhillipsECarosiGPREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030). 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, July 22–25, 2007, Sydney. Abstract WESS101.
12.
European Federation of Pharmaceutical Industries and Associations. Key messages surrounding pharmacogenetics. September 19, 2006.
13.
Vectibix (panitumumab). Package insert. Thousand Oaks, CA: Amgen, September 2006.
14.
GinsbergABrownTBillingsPLai-GoldmanM. Patient and provider readiness for pharmacogenomics: a user survey [abstract]. Am Soc Hum Genet. 2006.
15.
Bill HR 493: To prohibit discrimination on the basis of genetic information with respect to health insurance and employment. 110th Congress. January 16, 2007.
16.
GardinerSJBeggEJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?Pharmacogenet Genomics. 2005;15(5):365–369.
17.
MahlknechtUVoelter-MahlknechtS. Pharmacogenomics: questions and concerns. Curr Med Res Opin. 2005;21:1041–1047.
18.
ScienceProus. Lilly plans new phase III trial of Xigris. Prous Daily Essentials. February 28, 2007.
19.
Targeted therapies could make Rx companies more credible, Lilly exec says. Pink Sheet. June 27, 2007. FDC Publications.
20.
ConstableSJohnsonMRPirmohamedM. Pharmacogenetics in clinical practice: considerations for testing. Expert Rev Mol Diagn. 2006;6:193–205.
21.
RosesAD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004;5:645–656.
22.
RosesA. Pharmacogenetics in drug development: Alzheimer's disease. Abstract for presentation at 11th International Congress of Human Genetics, Brisbane, Australia, August 6–10.
23.
GoetzMPRaeJMSumanVJPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312–9318.
24.
GarberK. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst. 2005;97:412–413.
25.
CorriganOPWilliams-JonesB. Pharmacogenetics: the bioethical problem of DNA investment banking. Stud Hist Philos Biol Biomed Sci. 2006;37:550–565.
26.
RosesA. Personalized medicine: elusive dream or imminent reality?: a commentary. Clin Pharmacol Therapeutics. 2007;81(6):801–805.
27.
MelzerDDetmerDZimmernR. Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics. 2003;4:689–691.
28.
AnderssonTFlockhartDAGoldsteinDBDrug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559–581.
National Academy of Clinical Biochemistry. Guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Draft version 60806. 2007.
